An interventional study of ihtDEStiny® DES implanted and Xience™ DES implanted in Coronary Artery Disease, sponsored by Fundación EPIC. Recruiting at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Fundación EPIC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.
Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 30th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in United States, Belgium, Spain and 1 more country
Ages 18–85
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Hong Kong
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,100 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 13 interventional studies, 375 across the 20 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación EPIC is the lead sponsor of 48 studies on the registry; 19 are open to participants now.
10 of the studies in Coronary Artery Disease by Fundación EPIC that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448637Fundación EPICDRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) | 2026-12-01 |
| NCT05788432Fundación EPICSequent Extended Study | 2026-12-01 |
| NCT05617599Fundación EPICSUPRAFLEX CRUZ PMCF Study ( rEpic05 ) | 2026-12-01 |
| NCT06321757Fundación EPICPREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients | 2026-12-30 |
| NCT07260474Fundación EPICComparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 33 studies in Coronary Artery Disease by Fundación EPIC, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet ALL inclusion criteria will be included:
Exclusion Criteria:
Patients must not meet any of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: ihtDEStiny® DES implanted
Device: Xience™ DES implanted
ihtDEStiny® DES implanted
Xience™ DES implanted
EFFICACY: Device-oriented Composite Endpoint (DoCE)
Composite clinical endpoint cardiac Rate at 12 months cause death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)
Time frame: 12 months
NACE
Composite clinical endpoint Rate of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events
Time frame: 12 months
All-Cause Death Rate at 12 months
All-Cause Death Rate at 12 months
Time frame: 12 months
All-Cause Death Rate at 24 months
All-Cause Death Rate at 24 months
Time frame: 12 months
Cardiac Death Rate at 12 months
Cardiac Death Rate at 12 months
Time frame: 12 months
Cardiac Death Rate at 24 months
Cardiac Death Rate at 24 months
Time frame: 12 months
Myocardial Infarction Rate at 12 months
Myocardial Infarction Rate at 12 months
Time frame: 12 months
Myocardial Infarction Rate at 24 months
Myocardial Infarction Rate at 24 months
Time frame: 12 months
Periprocedural myocardial infarction Rate
Periprocedural myocardial infarction Rate
Time frame: PCI procedure
Definite/Probable stent thrombosis rate at 12 months
Definite/Probable stent thrombosis rate at 12 months
Time frame: 12 months
Definite/Probable stent thrombosis rate at 24 months
Definite/Probable stent thrombosis rate at 24 months
Time frame: 24 months
Any stroke at 12 months
Stroke Rate at 12 months
Time frame: 12 months
Any stroke at 24 months
Stroke Rate at 24 months
Time frame: 12 months
BARC type 2 ,3 or 5 bleeding events at 12 months
Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 12 months
Time frame: 12 months
BARC type 2 ,3 or 5 bleeding events at 24 months
Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 24 months
Time frame: 24 months
Target vessel revascularization Rate at 12 months
Target vessel revascularization Rate at 12 months
Time frame: 12 months
Target vessel revascularization Rate at 24 months
Target vessel revascularization Rate at 24 months
Time frame: 24 months
Target vessel Failure (TVF) Rate at 12 months
Target vessel Failure (TVF) Rate at 12 months
Time frame: 12 months
Target vessel Failure (TVF) Rate at 24 months
Target vessel Failure (TVF) Rate at 24 months
Time frame: 24 months
Target Lesion Failure (TLF) Rate at 12 months
Target Lesion Failure (TLF) Rate at 12 months
Time frame: 12 months
Target Lesion Failure (TLF) Rate at 24 months
Target Lesion Failure (TLF) Rate at 24 months
Time frame: 24 months
Target Vessel Revascularization Rate (TVR) at 12 months
Target Vessel Revascularization Rate (TVR) at 12 months
Time frame: 12 months
Target Vessel Revascularization Rate (TVR) at 24 months
Target Vessel Revascularization Rate (TVR) at 24 months
Time frame: 24 months
Target lesion ischemia-guided revascularization Rate at 12 months
Target lesion ischemia-guided revascularization Rate at 12 months
Time frame: 12 months
Target lesion ischemia-guided revascularization Rate at 24 months
Target lesion ischemia-guided revascularization Rate at 24 months
Time frame: 24 months
Repeated revascularization Rate at 12 months
Repeated revascularization Rate at 12 months
Time frame: 12 months
Repeated revascularization Rate at 24 months
Repeated revascularization Rate at 24 months
Time frame: 24 months
Major Adverse Cardiac Events (MACE) Rate at 12 months
Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 12 months
Time frame: 12 months
Major Adverse Cardiac Events (MACE) Rate at 24 months
Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 24 months
Time frame: 24 months
Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 45 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 45 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación EPIC